Latest Healthcare It News

Cleo Diagnostics has secured positive FDA feedback and nearly 1,600 biobank samples, accelerating its ovarian cancer blood test development ahead of a planned 2026 U.S. market entry.

Strategic Elements Ltd has marked a key milestone by successfully fabricating Energy Ink™ prototype cells in a commercial setting, while expanding its artificial intelligence ventures and maintaining a robust financial position.

HeraMED has bolstered its cash position with a $1.98 million capital raise and is on the cusp of finalizing two pivotal U.S. commercial agreements, signaling a major step forward for its digital maternity care platform.

Oakridge International reports robust Q1 2025 results with strong sales and technology advances, while managing a potential legal claim.

Vection Technologies reports a 60% surge in operating cash flow in Q1 FY26, driven by a landmark $22.3 million Defence framework agreement and a strategic $21 million capital raise. The company is poised for sustainable profitability with a record $75 million contract pipeline through 2028.

EVE Health Group has taken significant strides in commercialising its women’s and men’s health products Dyspro™ and Libbo™, securing regulatory clearances, first patient prescriptions, and raising $1.1 million to support market expansion.

Vitasora Health Limited reported robust patient program growth and secured new US partnerships, driving revenue above A$1 million for the quarter. A recent A$11 million capital raise positions the company for continued expansion and cash-flow breakeven by late 2026.

Uscom Limited reported a 27% drop in cash reserves for Q1 2025, driven by declining revenue and rising costs, while preparing to sell its main business unit to stabilize finances.

Micro-X Ltd has secured its largest-ever $3.3 million Rover Plus order from Malaysia’s Ministry of Health and is progressing critical Head CT imaging trials, supported by a $4.4 million government grant.

Enlitic, Inc. reported a strong quarter with record cash receipts and contract wins, yet withdrew its revenue guidance due to delayed project completions. The company remains confident in reaching operational cash flow break-even by the end of Q4 FY25.

Osteopore Limited reported a 7% year-on-year revenue increase in Q3 CY25, secured Swiss market approval for its implants, and saw a threefold sales surge through its Zimmer Biomet partnership.

BCAL Diagnostics has secured key partnerships and a $10 million convertible note facility to expand its cancer detection tests across Australia and New Zealand, marking steady commercial progress in Q3 2025.